Table 1.
Baseline characteristics of patients at the time of initiation of adalimumab therapy
| Parameter | Data analysis set N = 3,404 | Regression analysis set N = 2,625 |
|---|---|---|
| Age, years (SD) | 54.6 (12.7) | 54.6 (12.7) |
| Females, % | 77.7 | 77.4 |
| BMI, kg/m2 (SD) | 26.0 (4.8) | 25.9 (4.7) |
| Disease duration, years (SD) | 11.7 (9.2) | 11.7 (9.1) |
| Tender joint count (SD) | 12.4 (7.2) | 12.6 (7.2) |
| Swollen joint count (SD) | 9.6 (6.2) | 9.7 (6.2) |
| CRP, mg/L (SD) | 33.3 (62.7) | 33.4 (63.5) |
| ESR, mm/h (SD) | 34.2 (23.0) | 34.1 (22.7) |
| Rheumatoid factor | 77.7 | 78.2 |
| Erosive changes, % | 77.1 | 77.5 |
| Rheumatoid nodules, % | 26.0 | 26.0 |
| Joint replacement surgery, % | 16.9 | 16.6 |
| Patient global assessment-VAS (SD) | 6.5 (1.8) | 6.5 (1.8) |
| DAS28 (SD) | 5.9 (1.2) | 5.9 (1.1) |
| FFbH, % remaining functional capacity (SD) | 58.3 (23.1) | 59.0 (23.1) |
| Concomitant therapy | ||
| Any conventional DMARD, % | 74.5 | 76.1 |
| MTX, % | 54.2 | 56.4 |
| Leflunomide, % | 21.1 | 20.4 |
| Analgesics, % | 26.2 | 25.5 |
| NSAIDs (nonspecific), % | 45.0 | 45.8 |
| COX-2 inhibitors, % | 20.7 | 21.2 |
| Glucocorticoids, % | 86.0 | 85.6 |
Data are presented as mean values (standard deviation [SD]) unless otherwise indicated
BMI body mass index, COX-2 cyclo-oxygenase 2, CRP C-reactive protein, DAS28 Disease Activity Score-28 joints, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, FFbH Funktionsfragebogen Hannover functional capacity questionnaire, NSAIDs nonsteroidal anti-inflammatory drugs, VAS visual analog scale